Home treatment for Fabry disease: Practice guidelines based on 3 years experience in the Netherlands

Nephrology Dialysis Transplantation

Volumn 21, Issue 2, 2006, Pages 355-360

  Linthorst, Gabor E ^a   Vedder, Anouk C ^a   Ormel, Els E ^a   Aerts, Johannes M F G ^a   Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Non diabetic renal diseases; Treatment

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; DEXAMETHASONE; ENZYME ANTIBODY; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FABRY DISEASE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HOME CARE; HUMAN; HYPOTENSION; INFECTION; INFUSION REACTION; MALE; NETHERLANDS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHLEBITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; SKIN BRUISING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ALPHA-GALACTOSIDASE; FABRY DISEASE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HOME CARE SERVICES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES; TIME FACTORS;

EID: 31544463530     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi221     Document Type: Article

References (10)

1. Kint JA. Fabry's disease: Alpha-galactosidase deficiency. Science 1970; 167: 1268-1269
2. Desnick RJ, Ioannou YA, Eng ME. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. Vol. 3. McGraw-Hill, New York; 2001: 3733-3774
3. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
4. Schiffmann R, Kopp JB, Austin HA III et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. J Am Med Assoc 2001; 285: 2743-2749
5. Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: An international collaborative study of 33 patients. Blood 1993; 82: 1107-1109
6. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001; 358: 601-603
7. Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004; 66: 1589-1595
8. Linthorst GE, Hollak CEM, Ormel EE and Aerts JMFG. A comparative trial of two enzyme preparations for Fabry disease. Meeting of the European Study Group on Lysosomal Diseases, Podebrady 2003.
9. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999; 93: 2081-2088
10. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74